|
KR101628872B1
(ko)
|
2014-05-28 |
2016-06-09 |
주식회사 레고켐 바이오사이언스 |
자가-희생 기를 포함하는 화합물
|
|
US10973920B2
(en)
|
2014-06-30 |
2021-04-13 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
WO2016141230A1
(en)
|
2015-03-05 |
2016-09-09 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
CN107847605B
(zh)
|
2015-11-25 |
2021-12-24 |
乐高化学生物科学股份有限公司 |
包含分支接头的抗体-药物缀合物及其相关方法
|
|
JP7120765B2
(ja)
|
2015-11-25 |
2022-08-17 |
レゴケム バイオサイエンシズ， インク． |
ペプチド基を含む複合体及びそれに関連する方法
|
|
HUE067016T2
(hu)
|
2015-11-25 |
2024-09-28 |
Ligachem Biosciences Inc |
Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
|
|
EP3433259B1
(en)
|
2016-03-24 |
2021-06-30 |
The Administrators of The Tulane Educational Fund |
Conjugates of tacrolimus, their compositions, and their uses
|
|
EP3433278A4
(en)
*
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
|
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
KR20240010534A
(ko)
|
2016-08-09 |
2024-01-23 |
씨젠 인크. |
개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
|
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
|
EA201990890A1
(ru)
|
2016-10-18 |
2019-10-31 |
|
Целевая доставка ингибиторов реутилизационного пути никотинамидадениндинуклеотида
|
|
DK3529269T3
(da)
|
2016-10-19 |
2026-02-23 |
Invenra Inc |
Antistof-konstruktioner
|
|
FR3060567B1
(fr)
*
|
2016-12-19 |
2019-05-24 |
Ecole Normale Superieure De Lyon |
Substrat de glycosidase fluorogene et procede de detection associe
|
|
WO2018115485A1
(en)
|
2016-12-22 |
2018-06-28 |
Pierfrancesco Tassone |
A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
|
|
WO2018124758A2
(ko)
*
|
2016-12-28 |
2018-07-05 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
KR102085798B1
(ko)
|
2016-12-28 |
2020-03-06 |
주식회사 인투셀 |
베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
|
|
IL298414B2
(en)
|
2017-02-28 |
2024-12-01 |
Immunogen Inc |
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
|
|
CN110545850A
(zh)
|
2017-03-10 |
2019-12-06 |
奎亚培格制药公司 |
可释放的缀合物
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
|
|
JP7664680B2
(ja)
|
2017-03-29 |
2025-04-18 |
リガケム バイオサイエンシズ， インク． |
ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
|
|
WO2018201087A1
(en)
|
2017-04-27 |
2018-11-01 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
CA3061907A1
(en)
*
|
2017-05-02 |
2018-11-08 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
WO2019051488A1
(en)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
|
|
US11707531B2
(en)
|
2017-09-11 |
2023-07-25 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
CA3177215C
(en)
|
2017-09-29 |
2026-06-09 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
US10882915B2
(en)
|
2017-10-24 |
2021-01-05 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of CD117+ cells
|
|
AU2018374283B2
(en)
|
2017-11-29 |
2025-09-18 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of CD5+ cells
|
|
CA3084667A1
(en)
|
2017-12-15 |
2019-06-20 |
Silverback Therapeutics, Inc. |
Antibody construct-drug conjugate for the treatment of hepatitis
|
|
WO2019121734A1
(en)
*
|
2017-12-21 |
2019-06-27 |
Pharmacytics B.V. |
Method for improving the oral bioavailability of a drug
|
|
AU2019205325A1
(en)
|
2018-01-05 |
2020-08-13 |
Cybrexa 1, Inc. |
Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
|
|
BR112020015071A2
(pt)
*
|
2018-03-09 |
2021-01-05 |
Quiapeg Pharmaceuticals Ab |
Conjugados de anticorpos liberáveis
|
|
CN111936169A
(zh)
*
|
2018-04-06 |
2020-11-13 |
西雅图遗传学公司 |
喜树碱肽缀合物
|
|
EP3788050B1
(en)
|
2018-05-01 |
2024-08-28 |
Revolution Medicines, Inc. |
C26-linked rapamycin analogs as mtor inhibitors
|
|
PL3788049T3
(pl)
|
2018-05-01 |
2023-06-19 |
Revolution Medicines, Inc. |
Połączone z C40, C28 i C32 analogi rapamycyny jako inhibitory mTOR
|
|
US11827703B2
(en)
|
2018-05-09 |
2023-11-28 |
Legochem Biosciences, Inc. |
Compositions and methods related to anti-CD19 antibody drug conjugates
|
|
BR112020023136A2
(pt)
|
2018-05-14 |
2021-02-09 |
Nuvation Bio Inc. |
compostos de alvo de receptor de hormônio nuclear anticâncer
|
|
CN113227127A
(zh)
|
2018-06-05 |
2021-08-06 |
伦敦大学国王学院 |
向胃肠系统递送酬载的btnl3/8导引构建体
|
|
TWI920652B
(zh)
*
|
2018-06-07 |
2026-04-01 |
美商思進公司 |
喜樹鹼結合物
|
|
EP3826625A4
(en)
|
2018-07-23 |
2022-08-24 |
Magenta Therapeutics, Inc. |
USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENE CELL THERAPY
|
|
EP3849660A1
(en)
|
2018-09-12 |
2021-07-21 |
QuiaPEG Pharmaceuticals AB |
Releasable glp-1 conjugates
|
|
EP3849971A2
(en)
|
2018-09-12 |
2021-07-21 |
Silverback Therapeutics, Inc. |
Substituted benzazepine compounds, conjugates, and uses thereof
|
|
WO2020132658A2
(en)
|
2018-12-21 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Tubulysins and protein-tubulysin conjugates
|
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
MX2022000449A
(es)
|
2019-07-10 |
2022-04-25 |
Cybrexa 2 Inc |
Conjugados peptídicos de citotoxinas como terapéuticos.
|
|
BR112022000297A2
(pt)
|
2019-07-10 |
2022-03-15 |
Cybrexa 3 Inc |
Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
|
|
JP2022544543A
(ja)
|
2019-08-15 |
2022-10-19 |
シルバーバック セラピューティックス インコーポレイテッド |
ベンザゼピンコンジュゲートの製剤およびその使用
|
|
KR20210028544A
(ko)
|
2019-09-04 |
2021-03-12 |
주식회사 레고켐 바이오사이언스 |
인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
|
|
KR20220079606A
(ko)
*
|
2019-10-04 |
2022-06-13 |
씨젠 인크. |
캄프토테신 펩티드 접합체
|
|
US20210130473A1
(en)
|
2019-10-09 |
2021-05-06 |
Silverback Therapeutics, Inc. |
TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF
|
|
WO2021072330A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
|
|
EP4054561A4
(en)
|
2019-11-08 |
2023-12-20 |
North Carolina State University |
Cross-linking compounds and methods of use thereof
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110974975B
(zh)
*
|
2019-12-12 |
2023-10-20 |
成都百利多特生物药业有限责任公司 |
一种快速释放的抗体药物偶联物
|
|
CN114569735A
(zh)
*
|
2020-12-01 |
2022-06-03 |
泰州复旦张江药业有限公司 |
一种连接基-药物偶联物、制备方法及应用
|
|
JP7454110B2
(ja)
*
|
2020-12-04 |
2024-03-21 |
シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド |
抗体薬物複合体、その中間体、製造方法及び使用
|
|
WO2022126593A1
(zh)
*
|
2020-12-18 |
2022-06-23 |
上海复旦张江生物医药股份有限公司 |
一种靶向trop2的抗体药物偶联物、其制备方法及应用
|
|
US20240058463A1
(en)
*
|
2020-12-18 |
2024-02-22 |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
|
|
AR124475A1
(es)
|
2020-12-23 |
2023-03-29 |
Univ Muenchen Ludwig Maximilians |
Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos
|
|
EP4313991A1
(en)
|
2021-03-23 |
2024-02-07 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP4319755A4
(en)
|
2021-04-08 |
2025-03-26 |
Board of Regents, The University of Texas System |
Compounds and methods for theranostic targeting of parp activity
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
WO2022235585A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
CA3224492A1
(en)
|
2021-07-19 |
2023-01-26 |
Xiaojun Han |
Immunoconjugates and methods
|
|
US11806405B1
(en)
|
2021-07-19 |
2023-11-07 |
Zeno Management, Inc. |
Immunoconjugates and methods
|
|
CA3230737A1
(en)
|
2021-09-03 |
2023-03-09 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
|
EP4433096A1
(en)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
EP4460330A1
(en)
*
|
2022-01-06 |
2024-11-13 |
Virtuoso Binco, Inc. |
Conjugates, compositions and methods of use
|
|
WO2023194539A1
(en)
|
2022-04-07 |
2023-10-12 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
|
EP4531859A4
(en)
|
2022-05-25 |
2026-05-27 |
Revolution Medicines Inc |
CANCER TREATMENT METHODS USING AN MTOR INHIBITOR
|
|
AU2023298568A1
(en)
|
2022-06-30 |
2025-01-09 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
|
WO2024025396A1
(ko)
*
|
2022-07-28 |
2024-02-01 |
주식회사 레고켐 바이오사이언스 |
신규 오리스타틴 전구약물
|
|
CN119997982A
(zh)
|
2022-09-09 |
2025-05-13 |
迈里克斯制药有限公司 |
包含nmt抑制剂的抗体药物偶联物及其用途
|
|
CN117338949A
(zh)
*
|
2022-09-30 |
2024-01-05 |
成都百利多特生物药业有限责任公司 |
一种带有高稳定性亲水连接单元的奥瑞他汀类药物及其偶联物
|
|
WO2024121632A1
(en)
|
2022-12-09 |
2024-06-13 |
Crispr Therapeutics Ag |
Use of anti-cd117 antibody drug conjugate (adc)
|
|
WO2024189048A1
(en)
|
2023-03-13 |
2024-09-19 |
Heidelberg Pharma Research Gmbh |
Subcutaneously administered antibody-drug conjugates for use in cancer treatment
|
|
KR20240159448A
(ko)
|
2023-04-28 |
2024-11-05 |
주식회사 에이비켐바이오 |
균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법
|
|
KR20250074353A
(ko)
|
2023-11-20 |
2025-05-27 |
주식회사 에이비켐바이오 |
높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도
|
|
KR20240159447A
(ko)
|
2023-04-28 |
2024-11-05 |
주식회사 에이비켐바이오 |
말레이미드 함유 링커-페이로드 접합체
|
|
US20240424745A1
(en)
|
2023-06-22 |
2024-12-26 |
Cilag Gmbh International |
Systems and methods for attaching adjuncts to surgical staple cartridges using biocompatible adhesives
|
|
EP4543314A1
(en)
*
|
2023-06-22 |
2025-04-30 |
Cilag GmbH International |
Systems and methods for embedding medical additives into bioabsorbable materials
|
|
WO2025027529A1
(en)
|
2023-07-31 |
2025-02-06 |
Advesya |
Anti-il-1rap antibody drug conjugates and methods of use thereof
|
|
CN119424671A
(zh)
*
|
2023-08-01 |
2025-02-14 |
上海新理念生物医药科技有限公司 |
含糖基吡啶型连接子的抗体药物偶联物
|
|
JPWO2025058000A1
(enExample)
|
2023-09-13 |
2025-03-20 |
|
|
|
AR133955A1
(es)
|
2023-09-26 |
2025-11-19 |
Profoundbio Us Co |
Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos
|
|
TW202530255A
(zh)
|
2023-12-15 |
2025-08-01 |
法商亞維西亞有限公司 |
抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
WO2025171055A1
(en)
|
2024-02-06 |
2025-08-14 |
Kumquat Biosciences Inc. |
Heterocyclic conjugates and uses thereof
|
|
WO2025181219A1
(en)
|
2024-02-29 |
2025-09-04 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
WO2026039642A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|